Ranolazine Api

Product Description

Ranolazine is used to treat chronic angina. It may be used concomitantly with B blockers, nitrates, calcium channel blockers, antiplatelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.

The most common side effects are dizziness (11.8%) and constipation (10.9%). Other side effects include headache and nausea.

Ranolazine inhibits persistent or late inward sodium current (INa) in heart muscle in a variety of voltage-gated sodium channels. Inhibiting that current leads to reductions in elevated intracellular calcium levels. This in turn leads to reduced tension in the heart wall, leading to reduced oxygen requirements for the muscle.

Key Features of Ranolazine API

Ranolazine API is distinguished by its high level of purity (99%) and pharmaceutical-grade quality, making it ideal for medicinal use in the treatment of chronic angina. Packaged to preserve its stability, it maintains a shelf life of five years. The API is readily adaptable for different dosage forms and compatible with other common cardiac medications, supporting diversified clinical applications. Each batch complies with rigorous standards to guarantee patient safety and therapeutic effectiveness.


Therapeutic Applications and Benefits

Ranolazine is specifically used to manage chronic angina. Its unique mechanism of action helps improve blood flow to the heart without significantly affecting heart rate or blood pressure. The API is often combined with other standard heart medications, such as beta-blockers and calcium channel blockers, for enhanced symptom relief. Its broad acceptance among practitioners highlights its benefit in improving quality of life for patients with cardiac ischemia.